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Abstract
Background: Over one third of stroke patients have cognitive or language deficits such that they require surrogate
consent for acute stroke treatment or enrollment into acute stroke trials. Little is known about the agreement of
stroke patients and surrogates in this time-sensitive decision-making process. We sought to determine patient and
surrogate agreement in 4 hypothetical acute stroke scenarios.
Methods: We performed face to face interviews with ED patients at an academic teaching hospital from June to
August 2011. Patients and the surrogates they designated were asked to make decisions regarding 4 hypothetical
stroke scenarios: 2 were treatment decisions; 2 involved enrollment into a clinical trial. Percent agreement was
calculated as measures of surrogate predictive ability.
Results: A total of 200 patient/surrogate pairs were interviewed. Overall patient/surrogate percent agreement was
76.5%. Agreement for clinical scenarios ranged from 87% to 96% but dropped to 49%-74% for research scenarios.
Conclusions: Surrogates accurately predict patient preferences for standard acute stroke treatments. However, the
accuracy decreases when predicting research participation suggesting that the degree of surrogate agreement is
dependent on the type of decision being made. Further research is needed to more thoroughly characterize
surrogate decision-making in acute stroke situations.
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Background
By its nature, acute stroke treatment often involves
cognitively-impaired-patients who need to make urgent
decisions regarding high-risk-treatments within a short
window of time. In fact, over 35% of stroke patients have
acute cognitive or language difficulties that prohibit them
from consenting to emergency acute stroke treatments
[1]. Thus, acute stroke treatment decisions are often
made by surrogate decision-makers (patient proxies), who
are typically family members. Surrogate decision-making
based on “substituted judgment”—the idea that surrogates
choose the treatment the patient would most want to
receive—is commonly employed in many fields of medicine
to justify the treatment decisions that are made on behalf
of incapacitated patients. Utilizing substituted judgment is
a means by which medical professionals attempt to observe
the ethical principle of respect for persons and patient
autonomy in decision making.
Several studies have assessed the ability of surrogates
to accurately predict patients’ preferences regarding both
research participation [2,3] and the type of treatment in
the critical care setting [4-8]. A systematic review revealed
that surrogates predict ICU patients’ treatment preferences
with only 68% accuracy [9]. Both patient designation of
surrogates and prior surrogate-patient discussion of
patients’ preferences failed to improve surrogates’ accuracy
in predicting ICU patient desires [9]. Previous work on the
accuracy of surrogates in predicting patients’ consent for
research in the intensive care setting found false-positive
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(surrogate consenting when patient would not have)
consent rates for both a low-risk and a high-risk study to
be 16% and 20.3% respectively [3]. Other studies investigat-
ing surrogate ability to predict participation in clinical
research scenarios found that surrogates frequently
made decisions based on their own preferences and refused
research participation by proxy when it was in fact desired
[2,10]. Given significant observed discrepancies between
the choices of surrogates and patients, controversy exists as
to the importance, validity, and ethical integrity of obtain-
ing surrogate consent for incapacitated patients [11-13].
Given the time-sensitive nature of the condition, sur-
rogate consent for both treatment and research options
on behalf of cognitively-impaired-patients with acute stroke
is currently routine practice. The impact of surrogate
consent within the acute stroke setting has not previously
been investigated. We sought to determine the level of
patient-surrogate agreement given hypothetical standard
and experimental stroke treatment scenarios.
Methods
Setting
We performed cross-sectional surveys via face-to-face
interviews of patients and their self-designated surro-
gates in the University of Michigan Hospital Emergency
Department (ED) between June and August 2011.
Participant identification
Patients were screened in the ED based on chief complaint
and vital signs obtained from the ED electronic information
system. Adult patients (ages 18 and over) were eligible for
inclusion if they presented to the ED without a diagnosis of
stroke or altered mental status, and with stable vital signs.
In addition, participants had to be accompanied by a family
member, friend, or significant other who might act as the
surrogate decision maker in a real life setting.
Scenarios
The scenarios were developed and then pilot-tested using
semi-structured interviews in a small group of healthy,
community dwelling individuals. Feedback regarding
scenario wording and clarity informed adjustments to
the scenarios and questions. Briefly, scenarios 1 and 2
asked the participants a treatment question only with no
research element. Specifically, scenario 1 presented a choice
between IV tPA and no treatment for stroke, while scenario
2 presented the treatment options of IV tPA or an endo-
vascular clot removal procedure.
Scenarios 3 and 4 involved deciding between standard
IV tPA and an experimental treatment within the context
of a research trial. Scenario 4 was identical to scenario 3,
except randomization in scenario 3 was fixed at 50:50 and
response adaptive randomization was described for scenario
4. Response adaptive randomization changes the allocation
ratio based on information accumulated during the
trial to randomize more patients to whichever arm is
performing better (possibly the active treatment or the
control) [14]. The exact wording of the scenarios is avail-
able in Additional file 1.
Interview procedures
After verbal informed consent was obtained, the surrogate
was asked to leave the area. The patient was first asked
if he/she could identify any of the warning signs of
stroke, in order to assess his/her current knowledge of
stroke symptoms [15]. Adequate stroke knowledge was
defined as the ability to name two of five acute stroke
symptoms (headache, paralysis, trouble speaking/confusion,
vision changes, and dizziness). The patient was then
presented with the four scenarios for decisions in the
event of an acute stroke. The scenarios and data collection
instrument are available as a web appendix.
After each scenario, the designated patient was asked to
indicate his or her preferred treatment or research choice
between the two offered. He/she was then presented with
a 10-point Likert scale and asked to indicate his/her confi-
dence in that decision—that he or she had made the right
choice (0 = not at all confident, 10 = absolutely confident).
The same scenarios were then presented to the surrogates,
in the same order and with identical wording. Additionally,
surrogates were asked to indicate their certainty that
the patient made the same treatment or research choice.
Again, a 10-point Likert scale was used for assessments
(0 = completely unsure, 10 = completely sure). Patients
and surrogates were allowed to ask questions regarding the
scenarios before making decisions; the study team created
a set of standard answers to the most commonly asked
questions after the first week of recruitment. Demographics
for patients/surrogates were collected after the completion
of the interviews. No protected health information or
specific patient or surrogate identifiers were collected. Zip
codes were collected in order to estimate household in-
comes of the communities in which the patients and surro-
gates resided, using the census.gov website [16].
Statistical analysis
The primary outcome variable was the overall weighted
Cohen’s kappa statistic for agreement between patient
and surrogate. This was calculated for each of the four
scenarios. Other collected data, including demographic
information and responses to the Likert scales for confi-
dence and certainty of decisions made was summarized
using means with standard deviation or proportions as
appropriate. In addition, we also calculated Gwet’s AC1
which addresses the problem of a kappa statistic in low
prevalence situations [17-19].
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Sample size calculation
We hypothesized that modest agreement would occur at
baseline (kappa = 0.5) [16]. We assumed that patients
would consent to hypothetical treatments or research
trials 80% of the time, and that surrogates would consent
70% of the time. Based on our assumptions and using the
N.cohen.kappa function from the Concord package of R
Version 2.8.1, we estimated 90% power to detect a kappa
statistic of 0.7 or higher with a total sample size of 200.
We doubled this sample size to be conservative as we
were aware of no prior pilot data that provided estimates
of the performance of surrogate consent in acute stroke
research.
Human subjects protection
The study protocol was reviewed and approved by the
University of Michigan Institutional Review Board and was
granted Exempt status. Potential participants were provided
with an information sheet describing the study and in-
dicating that participation was completely voluntary. In
addition, patients were assured that treatment for their
presenting complaints would not be compromised by
declining to participate. Participants were given the
opportunity to have questions answered, and if they
agreed, verbal consent was obtained.
Results
Subject characteristics
400 participants were enrolled in the study—200 “patients”
and 200 “surrogates.” Characteristics of both are shown in
Table 1. Stroke knowledge was similar between the patient
and surrogate groups, with 71% and 74%, respectively,
of patients and surrogates able to provide at least 2 out
of 5 possible stroke symptoms. Mean community household
income was the same for patients and surrogates at $54,144
and is higher than the national average of $41,994 [16].
Patient and surrogate decisions
Overall, surrogates predicted patients’ treatment prefer-
ences with 76.5% crude agreement; however, the kappa
statistics for each scenario indicated poor agreement. The
kappa statistics ranged from 0.18 in scenario 1 to −0.02 in
scenario 4. The full results for each scenario are presented
in Table 2. In scenario 1 in which subjects were given
the choice between being given tPA or undergoing no
treatment, surrogates had 96% prediction accuracy; the
overwhelming majority of patients and surrogates chose
the treatment of tPA over no treatment. Patient/surrogate
agreement in scenario 2 (clot removal procedure vs. tPA)
was 87%; the vast majority of agreement was found
when both parties refused the procedure and opted for
tPA instead.
In scenario 3 (tPA vs. standard RCT), 5% of patient/
surrogate pairs consented to the trial while 70% of pairs
refused the trial, resulting in an agreement rate of 74%. The
majority of disagreement (65%) was found when patients
desired the trial but proxies refused. Lastly, scenario 4
(tPA vs. adaptive RCT) represented the lowest rate of
surrogate/proxy agreement at 49%, (pairs consenting to
trial 28.5%, pairs refusing trial 20.5%) although there was
higher overall consent to the trial in patients (56%) and
proxies (50%) when compared to the standard RCT.
Sensitivity and specificity were both 49%.
Patients and surrogates all indicated relatively high
degrees of confidence (mean confidence scores for each
scenario ranged from 7.8 to 8.5 on a 10-point Likert scale)
Table 1 Patient and surrogate characteristics
Patients Surrogates
Characteristics N % N %
Female 122 61% 120 60%
Male 78 39% 80 40%
Ethnicity
White 178 89.5% 179 89.5%
African American 14 7% 14 7%
Hispanic 2 1% 2 1%
Asian 3 1% 2 1%
Other 3 1.5% 3 1.5%
Education
Some high school 14 7% 8 4%
High school graduate 39 19.5% 44 22%
Some college 77 38.5% 61 30.5%
College graduate 44 22% 53 26.5%
Post graduate degree 26 13% 34 17%
Medical history
Myocardial infarction 15 7.5% 5 2.5%
Diabetes 24 12% 15 7.5%
Stroke 6 3% 8 4%
Hypertension 49 24.5% 44 22%
Atrial fibrillation 14 7% 4 2%
None of the above 132 66% 144 72%
Surrogate relationship to patient
Spouse 83 41.5%
Child 24 12%
Parent 29 14.5%
Sibling 10 5%
Significant other 21 10.5%
Other 28 14%
Mean SD Mean SD
Age, years 46.4 18.4 47.2 16
Number of siblings 2.5 1.8 2.4 1.9
Median household income $54,144 $14,818 $54,144 $13,464
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Table 2 Agreement between patients and surrogates for hypothetical stroke scenarios
Scenario 1: TPA vs. no treatment Scenario 2: TPA vs. clot removal procedure Scenario 3: TPA vs. standard RCT Scenario 4: TPA vs. adaptive RCT
Patients Patients Patients Patients
Proxies
Would you
want TPA?
Yes No
Proxies
Would you want
the procedure?
Yes No
Proxies
Would you
want the trial?
Yes No
Proxies
Would you
want the trial?
Yes No
Yes
95.5%
(n = 191)
2%
(n = 4)
Yes
1%
(n = 2)
4.5%
(n = 9)
Yes
4.5%
(n = 9)
9%
(n = 18)
Yes
28.5%
(n = 57)
21.5%
(n = 43)
No
2%
(n = 4)
0.5%
(n = 1) No
8.5%
(n = 17)
86%
(n = 172) No
17%
(n = 34)
69.5%
(n = 139) No
29.5%
(n = 59)
20.5%
(n = 41)
Mean SD Mean SD Mean SD Mean SD
Patient confidence 8.0 2.1 Patient confidence 8.1 2 Patient confidence 8.0 1.9 Patient confidence 7.8 1.9
Proxy confidence 8.5 1.7 Proxy confidence 8.5 1.9 Proxy confidence 8.4 1.9 Proxy confidence 8.0 1.9
Proxy certainty 8.4 1.9 Proxy certainty 8.0 2.2 Proxy certainty 7.8 2.3 Proxy certainty 7.5 2.1
Cohen’s
Kappa statistic
0.18
Cohen’s
Kappa statistic
0.07
Cohen’s
Kappa statistic
0.11
Cohen’s
Kappa statistic
−0.02
AC1 (95% CI) 0.96 (0.93-0.99) AC1 (95% CI) 0.87 (0.79-0.91) AC1 (95% CI) 0.63 (0.53-0.74) AC1 (95% CI) −0.01 (−0.13 – 0.13)
Overall agreement is observed in the bolded diagonal cells (i.e for scenario 1: 96% of patients and proxies agreed). Counts and proportions listed for all scenarios. Patient and surrogate confidence was measured on a
10 point Likert scale. SD = standard deviation. tPA = tissue plasminogen activator. RCT = Randomized controlled trial. AC1 = Gwet’s agreement coefficient. CI = confidence interval.
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in the decisions they were making. In addition, surrogates
indicated that they were reasonably certain (mean certainty
ranged from 7.5 to 8.4) that their decisions would be in
concordance with the patients’ wishes.
Discussion and conclusions
Our study of 200 patient/surrogate pairs found substantially
more patient/surrogate agreement in scenarios involving
standard treatments (scenarios 1 and 2) than for research
protocols (scenarios 3 and 4). The varying predictive
accuracy of surrogate decision-makers demonstrated
in other studies raises questions about the ethics and
validity of charging surrogates with important medical
decisions, especially in an acute setting such as stroke
[4,11]. Some ethicists argue against the use of surrogates
as the decisional authority for incapacitated patients and
recommend instead that surrogates serve as advisors to the
medical team, who will carry out “best-interests judgment”
on behalf of the patient; this is less clear regarding research
participation [13]. The results of the current investigation
suggest surrogates predict patient preferences for standard
treatments well and perform less well when trying to
predict patient preferences for research participation. It
is likely that the degree of surrogate agreement is highly
dependent on the type of decision being made.
When given a choice, the majority of patients and
surrogates opted for standard treatments (tPA) over more
experimental (scenario 2) or clinical trial (scenarios 3 and
4) alternatives. Possible explanations for this result could
be risk aversion given the severe nature of the described
stroke and/or time pressure to make potentially life and
death decisions, leading participants to “stick with the
standard” rather than choosing a newer, riskier, and often
more complex alternative that would have required more
thought [2,10]. Furthermore, the nature of our interview
study limited the amount of information we could give
participants regarding treatments and trials; participants
may have opted for more standard treatments simply
because they felt that not enough information was provided
for the alternative research treatments. Our results echo
the findings of several other studies in that surrogates
predicted more frequently on the conservative side, (e.g.,
refusing research trial participation) when the patients
themselves would have chosen (potentially riskier) research
over standard treatment [2,10].
The clinical trial featuring response adaptive random-
ization (scenario 4) was more often agreed to by both
patients and surrogates than the standard clinical trial
(scenario 3), although there was substantially more dis-
agreement regarding participation in the adaptive trial.
It is possible that the complexity of the adaptive trial,
confusion regarding its setup, and difficulty explaining
it could have contributed to the observed discrepancy.
Interestingly, scenario 4 represented the lowest rate of
patient/surrogate agreement and also represented the
lowest confidence in decision ratings from both patients
and proxies. Proxy certainty that their decision was in
accordance with the patient’s decision was also lowest
in scenario 4 in comparison to the other scenarios. This
suggests that patients and proxies are to some degree
calibrated regarding the validity of their decisions, and that
lack of proxy certainty is correlated with poor predictive ac-
curacy. The therapeutic misconception (potential research
volunteer belief that a research protocol confers medical
benefit) has previously been described as a concern that
response adaptive randomization may help mitigate [20];
we did observe numerically higher participation in the
RAR scenario versus the fixed randomization design.
We recognize several limitations of our study. The pre-
cision of our estimates of agreement via the kappa statistic
was limited, mainly because of the high prevalence of
acceptance of standard treatments and the low prevalence
of acceptance of research protocols by both patients and
surrogates. This phenomenon is known as the “kappa
paradox” and occurs in settings where the prevalence
of a “yes” response is very high (i.e., consenting to the
standard treatment of tPA) or very low (i.e., refusing
participation in the research trials) [21]. The high or low
prevalence of “yes” responses results in a high likelihood
that agreement between surrogates and patients occurred
by chance alone—a point that when taken into account by
kappa results in low kappa statistics despite high rates of
agreement between groups. For this reason, the Cohen
kappa statistics here do not adequately reflect the degree
of agreement between patients and surrogate decision-
makers. Our calculations of the AC1 may provide a
more meaningful picture, indicating fairly good to excellent
agreement on scenarios 1 to 3. Another limitation is that
our secondary measurements of certainty and confidence
were on the Likert scale, and required that participants
make probability estimations by choosing from ordinal
numbers from 0 to 10. An additional limitation is that
hypothetical scenarios raised many questions from subjects
that likely caused participants to receive more, less, or
different information than others. Although we developed
a set of answers to commonly asked questions early in the
study in an effort to standardize information as much as
possible, it is not possible to anticipate every question
for every discrete treatment or trial. In fact, this reflects the
“real world” consent process. Furthermore, participants
were not provided with an option for “undecided.” This
undoubtedly forced participants into decisions they
were not comfortable with or did not fully understand.
However, this is identical to what happens in the setting of
actual acute stroke. Finally, since these scenarios were
hypothetical, it is unclear how our research would
compare to patient/surrogate decisions in actual acute
stroke presentations.
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As to the generalizability of this study, the population
was recruited from the area surrounding the University of
Michigan Medical Center, and was therefore on average
more educated, predominately Caucasian, and lived in areas
of higher median income than the overall US population.
Thus, the results of this study may not be generalizable to
other, more urban or rural medical centers. Furthermore,
patient/surrogate pairs were younger than typical stroke
patient/surrogate pairs, potentially leading to results that
do not reflect the preferences of the actual stroke victims
and their surrogates in clinical practice. This is important
to consider as the young may discount the quality of life of
older adults – therefore adult children may act differently
as surrogates decision makers compared to spouses/
significant others.
In summary, patient/surrogate agreement varies depend-
ing on the type of clinical or research decision being made.
Future research might investigate how patient/surrogate
agreement compares to patient/physician agreement as
medical providers are the most likely alternative decision
makers when surrogates cannot be identified. An additional
important area for future research is the degree to which
potential research subjects understand the trial designs.
Further research designs may benefit from a mixed methods
approach to explore in more detail the nature of patient/
surrogate discrepancies in order to develop a conceptual
model for surrogate decision-making in acute settings.
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